DMS Pharmaceutical Group Inc.
Park Ridge, IL
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 810 Busse Hwy, Park Ridge, IL 60068, USA
- Website
- dmspharma.com
- Founded
- 1995
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 51 Wholesale Trade – Nondurable Goods
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $207,542,807 |
| FY2025 | $293,097,115 |
| FY2024 | $260,076,670 |
| FY2023 | $255,622,571 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Logistics Agency | $207,542,807 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cardinal Health, Inc. | Dublin, OH | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Defense Logistics Agency - Troop Support | Philadelphia, PA | 445298 All Other Specialty Food Retailers |
| Mckesson Drug Company | — | 325412 Pharmaceutical Preparation Manufacturing |
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Corporate Office | Conshohocken, PA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
DMS Pharmaceutical Group Inc., a woman-owned small business headquartered in Park Ridge, Illinois, is the sole regional prime vendor under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), supplying branded and generic prescription drugs, biologics, vaccines, over-the-counter medications, and medical consumables to Department of Defense military healthcare facilities worldwide as a prime contractor on a single-award indefinite delivery contract.
DMS Pharmaceutical operates under contract SPE2DX, a Defense Logistics Agency indefinite delivery vehicle awarded April 24, 2026, with a ceiling value of $4.999 million (note: the source data reflects a placer-ceiling notation reflecting the parent vehicle's unbounded scope) and ultimate completion through December 31, 2036. The contract structure includes a 30-month base period and three 30-month option periods, with place of performance in Park Ridge, Illinois, and work executed worldwide to support military healthcare operations at domestic and overseas locations. NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers) and PSC 344 (Drugs and Biologicals) classify the primary work.
DMS Pharmaceutical's federal footprint is entirely concentrated in pharmaceutical supply-chain delivery orders. The Defense Logistics Agency Troop Support Medical function and Defense Logistics Agency proper collectively account for 100% of awards, with Defense Logistics Agency Troop Support Medical dominating the volume (326,663 awards, $107.8 billion combined potential value) and Defense Logistics Agency accounting for 58,648 awards valued at $47.67 billion combined potential. Recent representative delivery orders span high-value specialty biologics—Keytruda ($50.8 thousand), Botox ($26.4 thousand to $79.6 thousand), Xolair ($3.5 thousand to $5.2 thousand), Entyvio ($99.3 thousand), and Trikafta ($38.6 thousand)—alongside generic and over-the-counter medications with unit order ceilings ranging from single dollars to tens of thousands. The 386,148 total awards in the source represent a transactional supply model driven by monthly or recurring delivery orders rather than multi-year prime contracts. All awards are prime designations; no subcontract activity appears in the portfolio.
The top five vehicle IDCs show task-order distribution across the PPV-G GEN V acquisition strategy: SPE2DX15D9383 (61,527 task orders, $80.6 million combined potential value), SPE2DX15D9901 (16,070 task orders, $63.9 million), SPE2DX15D9628 (12,043 task orders, $66.7 million), SPE2DX15D9905 (20,016 task orders, $25.9 million), and SPE2DX16D9991 (9,959 task orders, $4.8 million). These vehicles represent legacy and current tranches of the multi-regional pharmaceutical prime vendor program. Activity has remained steady—39,913 awards in 2022, declining to 36,533 in 2024 and 22,036 year-to-date in 2026 (reflecting a partial-year count through July). Only one award with combined potential value of $248 thousand completes in the next twenty-four months, indicating minimal recompete exposure in the near term; the broad base of work extends through 2036.
The portfolio reflects DMS Pharmaceutical's operational model as a pharmaceutical distributor executing transactional delivery orders rather than managing large system-integration or professional-services contracts. Category concentration by NAICS mirrors supply-chain roles: 197,394 awards coded to Drugs and Druggists' Sundries Merchant Wholesalers, 119,133 to Medicinal and Botanical Manufacturing (reflecting co-codes on pharmaceutical line items), and 64,235 to Pharmaceutical Preparation Manufacturing. PSC codes show 354,248 awards tagged to Drugs and Biologicals (PSC 344), with the remainder distributed across medical instruments and supplies. No set-aside designation appears on any award; DMS Pharmaceutical competes full-and-open on this vehicle despite its woman-owned small business status.
SBA capabilities narrative
DMS is a full-line, woman-owned pharmaceutical wholesaler serving the brand and generic drug needs of nationwide customers: hospitals, closed pharmacies, long-term care facilities, and surgery centers.
Quick answers
Is DMS Pharmaceutical Group Inc. registered in SAM.gov?
Yes. DMS Pharmaceutical Group Inc.'s SAM.gov registration is active through February 23, 2027.
What is DMS Pharmaceutical Group Inc.'s CAGE code?
DMS Pharmaceutical Group Inc.'s CAGE code is 1UNB0, and its Unique Entity ID (UEI) is PX72BSBQTKJ3.
How much has DMS Pharmaceutical Group Inc. received in federal contracts?
Federal contracts obligated $293,097,115 to DMS Pharmaceutical Group Inc. in fiscal year 2025 and $1,016,339,163 in fiscal years 2023 through 2027.
How does DMS Pharmaceutical Group Inc. rank among federal contractors?
DMS Pharmaceutical Group Inc. ranked #2 in NAICS 424, #3 in PSC 6505 and #3 in NAICS 325411 in FY2025.
What is DMS Pharmaceutical Group Inc.'s most recent federal award?
DMS Pharmaceutical Group Inc.'s most recent federal contract award is Amox-clav 875-125 MG tablet 20S (SPE2D326F355Y), from Medical Supply Chain (DLA), on August 6, 2026.
On GovTribe
See DMS Pharmaceutical Group Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors